ReviewCancer immunology, immunotherapy : CII2009
Cancer, aging and immunotherapy: lessons learned from animal models.
Review in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.Cancer immunology, immunotherapy : CII · 2018Trial
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2022Article
- Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.Journal of thoracic disease · 2020Article
- Catalog of Lung Cancer Gene Mutations Among Chinese Patients.Frontiers in oncology · 2020Article
- Neutrophil-lymphocyte ratio change after curative gastrectomy for gastric cancer: a subgroup analysis.Einstein (Sao Paulo, Brazil) · 2020Article
- Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?Blood cancer journal · 2019Article
- The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.Frontiers in medicine · 2018Article
- Age-associated impairment of antitumor immunity in carcinoma-bearing mice and restoration by oral administration of Lentinula edodes mycelia extract.Cancer immunology, immunotherapy : CII · 2016Article
- Growth and Metastasis of Intraocular Tumors in Aged Mice.Investigative ophthalmology & visual science · 2016Article
- Aging, cancer, and cancer vaccines.Immunity & ageing : I & A · 2012Article
- Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.Cancer research · 2012Article
- Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction.Aging cell · 2012Article
- The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.Cancer immunology, immunotherapy : CII · 2011Article
- Epidemiologic perspective on immune-surveillance in cancer.Current opinion in immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Aging of the immune system is associated with a dramatic reduction in responsiveness as well as functional dysregulation. This deterioration of immune function with advancing age is associated with an increased incidence of cancer. Although there is a plethora of reports evaluating the effect of immunotherapy in stimulating antitumor immune responses, the majority of these studies do not pay attention to the effect aging has on the immune system. Studies from our group and others indicate that immunotherapies could be effective in the young, are not necessarily effective in the old. To optimally stimulate an antitumor immune response in the old, it is necessary to (1) identify and understand the intrinsic defects of the old immune system and (2) use relevant models that closely reflect those of cancer patients, where self-tolerance and aging are present simultaneously. The present review summarizes some defects found in the old immune system affecting the activation of antitumor immune responses, the strategies used to activate stronger antitumor immune response in the old and the use of a tolerant animal tumor model to target a self-tumor antigen for the optimization of immunotherapeutic interventions in the old.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.